STALICLA SA: STALICLA Appoints Baltazar Gomez-Mancilla, MD, PhD, as Chief Medical Officer
Appointment will benefit STALICLA s robust drug discovery platform and pipeline development
STALICLA SA, a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), announced today the appointment of Baltazar Gomez-Mancilla, MD, PhD, to the position of Chief Medical Officer. Dr. Gomez-Mancilla, whose clinical neuroscience leadership includes more than 25 years of experience in the pharmaceutical industry, will help advance clinical trials leveraging the deployment and application of STALICLA s first-in-class precision drug discovery platform DEPI, with an initial application in Autism Spectrum Disorder (ASD). Joining a world-class team of 26 seasoned drug developers, clinicians, data scientists and computational biologists, Dr. Gomez-Mancilla brings invaluable insight from previous roles that in
Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Published: May 05, 2021
WATERTOWN, Mass., May 05, 2021 (GLOBE NEWSWIRE) Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Juliet Williams, PhD, as Senior Vice President, Head of Biology. Dr. Williams joins Kymera with 20 years of experience in the biopharmaceutical industry, including leadership roles in drug discovery and translational development.
“I’m very excited to welcome Juliet to the leadership team at Kymera,” said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. “Juliet has been a successful drug hunter in both biotech and large pharma. Her expertise and leadership in target identification, drug discovery, and translational drug development across small molecule and innovative drug classes will be invaluable as we continue to expand Kymera’s capabilities to build a
(Loxo Oncology)
Josh Bilenker, M.D., and Jeff Engelman M.D., Ph.D., have joined forces to create a new cancer biotech, tapping their combined considerable experience to find new solutions to old oncology research problems.
These are big names: Bilenker was until the start of the year Lilly’s cancer R&D chief, put in that position after the Big Pharma ponied up $8 billion for Bilenker’s startup Loxo Oncology two years back.
It seems Bilenker wants to get back to biotech and is taking Novartis’ vice president and global head of oncology Engelman, who also directs cancer drug discovery at the Novartis Institutes for BioMedical Research, along with him.
Translational Research in Oncology: TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial
Over 5000 Patients Enrolled in 20 countries
EDMONTON, Alberta, April 21, 2021 (GLOBE NEWSWIRE) Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial, referred to as NATALEE (New Adjuvant TriAl with LEE), has enrolled 5101 patients globally.
Rapid enrollment of this randomized, phase III study can be attributed to the strength of TRIO s global network consisting of 405 active investigator sites, including TRIO-US and its regional partners, and current unmet needs among the eBC patient population that includes intermediate-risk patients, as well as high-risk stage III patients.
vimarsana © 2020. All Rights Reserved.